Search | Page 3 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Sapacitibine shows promise for high-risk MDS patients

    ... performance status, and International Prognostic Scoring System (IPSS and IPSS-Revised) subgroup classification. The main goal of MDS therapy is to provide symptom control ... agents, especially in the setting of patients who are not HSCT eligible, is a poor prognostic sign. Median survival is ...

    Research Review last updated 05/02/2016 - 9:30am.

  2. Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non-Hodgkin's Lymphoma

    ... indolent lymphoma including follicle cell lymphoma, WHO classification, grade I or II, and marginal zone lymphoma. Bone marrow ...

    Clinical Trial last updated 06/06/2016 - 10:17am.

  3. Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia

    ... AML (any number of relapses) including patients who may have been previously exposed to one or more FLT3-inhibitor therapies ... of AML regardless any prior therapy for AML. The WHO classification will be used for AML. Patients must be eligible for one of ...

    Clinical Trial last updated 05/23/2016 - 3:37pm.

  4. 8-Chloro-Adenosine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

    ... have a diagnosis of AML as per World Health Organization (WHO) Classification of Hematologic Neoplasms Patients must meet one of the ...

    Clinical Trial last updated 05/23/2016 - 3:25pm.

  5. Initial transfusion dependence predicts survival in myelodysplastic syndrome

    ... patients as higher versus lower risk disease. Patients who had higher ITI had higher transfusion dependence throughout their course ... classified as higher risk by ITI, independent of their IPSS classification. Incorporation of the ITI into the IPSS and other scoring ...

    Research Review last updated 05/02/2016 - 9:17am.

  6. Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies.

    ... at diagnosis; Any unfavorable sub type by FAB or WHO classification; High-risk cytogenetics (eg those associated with ...

    Clinical Trial last updated 04/29/2016 - 3:51pm.

  7. Identification of genetic abnormalities in MDS patients that may lead to a better diagnosis and treatment strategy of MDS patients

    ... and or progression, and they are not part of the MDS classification systems.  However, some of these genetic abnormalities (in ... in the TET2 gene in their blood cells compared to the group who did not have this mutation.  Mutations that can predict therapeutic ...

    Research Review last updated 05/02/2016 - 9:23am.

  8. Insights into the Natural History of Paroxysmal Nocturnal Hemoglobinuria (PNH): Analysis of the Presenting Clinical, Haematological and Flow Cytometric Features of 705 Patients Leads to Improved Classification and Prediction of Clinical Course

    ... Pancytopenia is common in patients with PNH who have aplastic anemia or hemolytic anemia, and the two groups have similar ... of PNH in more than 95% of patients. A PNH classification system based on the degree of aplasia (decreased or no production of blood ...

    Research Review last updated 05/02/2016 - 9:20am.

  9. HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy (RAFA)

    ... Myelodysplastic Syndrome (MDS) (based on WHO or IPSS Classification Acute Myelogenous Leukemia (untreated, in remission ...

    Clinical Trial last updated 05/09/2016 - 3:19pm.

  10. Vosaroxin for Intermediate 2 or High-risk MDS After Failure With Hypomethylating Agent-based Therapy

    ... , peripheral blood, or both) by World Health Organization (WHO) classification with an intermediate 2 (INT-2) or high-risk score (ie, ≥ 1.5) ...

    Clinical Trial last updated 04/29/2016 - 1:36pm.